Sharemaestro Newsreel

Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker

Balyasny Asset Management and its related entities have disclosed a beneficial ownership of approximately 4.99% in Camp4 Therapeutics Corp. (CAMP). This stake, totaling 2,591,097 shares, includes common stock and shares issuable upon warrant exercise, which are subject to a 4.99% Beneficial Ownership Limitation to …

Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership

Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. …

Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views

Analysts have raised their fair value estimate for Fennec Pharmaceuticals (FENC) from US$15.33 to US$17.67 per share, attributing this increase to stronger-than-expected PEDMARK revenue, its expanded use across various tumor types, and improved operating leverage. Several firms, including B. Riley, Wedbush, and H.C. Wainwright, …

Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value

Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report …

Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership

Balyasny Asset Management L.P. and its affiliated entities have reported a 6.03% beneficial ownership stake in Crescent Biopharma, Inc., totaling 1,662,917 shares of Class A common stock. This ownership is primarily held through Atlas Private Holdings (Cayman) Ltd. and Atlas Diversified Master Fund, Ltd. …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Four Innate Pharma executives set to appear in Aug. 14 webcast

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares jumped over 60% after its CEO indicated the FDA is open to reviewing an updated Duchenne muscular dystrophy cell therapy submission. Separately, Cytokinetics is suing Bristol Myers Squibb to protect patents for its heart drug Myqorzo, accusing BMS of attempting to …

Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages

Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.91. Despite a recent 3.9% decline in shares and missing analyst expectations for its quarterly loss, institutional investors hold a significant 67.78% of the …

Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)?

Trevi Therapeutics, Inc. reported wider net losses and basic loss per share in Q2 2026, alongside filing a US$149.2 million shelf registration for 8,000,000 common shares. This new financing overhang adds to existing concerns about potential dilution and weighs against the company's investment narrative, …

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX

Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company …

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Report - Results, Call & Slides

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS

Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial

Fractyl Health (NASDAQ:GUTS) is advancing two one-time treatments for obesity, type 2 diabetes, and metabolic diseases. The company expects pivotal data for its lead program, Revita, in early Q4, with a focused commercial rollout planned if approved. Additionally, its gene therapy platform, Rejuva, has …

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts

Kyverna Therapeutics (NASDAQ:KYTX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $30.00, significantly above its current price of $8.08. Insider ownership has increased, with hedge funds and institutions owning 18.08% of the stock. The company recently …

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages

Palisade Bio, Inc. (NASDAQ:PALI) has received a consensus "Buy" recommendation from brokerages, with an average one-year target price of $9.00. The article details recent analyst ratings, including several "buy" and "strong-buy" recommendations, alongside some changes to "hold" and "sell" ratings. It also highlights recent …

AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85%

Hyperion DeFi (HYPD) Q2 2026 Earnings Call: Adjusted Gross Profit Rises 20%

Stock index futures largely flat after S&P 500 closes at record high

[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) …

Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX

Assenagon Asset Management S.A. significantly reduced its stake in REGENXBIO Inc. by 82.7% in the second quarter, now holding 169,279 shares valued at $2.03 million. Despite this, institutional investors still own a substantial 88.08% of the company. REGENXBIO recently surpassed analyst estimates for quarterly …

Cibus (CBUS) Q2 2026 Earnings Call: Rice Launch Moves to 2028 as Costs Decline

Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA

Bank of America Corp DE increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 6.6% in the first quarter, now owning 1,619,994 shares valued at approximately $37.75 million. Institutional investors and hedge funds collectively own 99.12% of Innoviva, and the stock currently has an average …

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate …

Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson

Janus Henderson Group Ltd. filed an amended beneficial ownership report (SCHEDULE 13G/A) for Dyne Therapeutics Inc. (DYN), indicating that its affiliated asset managers beneficially own 11,997,738 shares, representing 7.3% of the class as of June 30, 2026. These shares are held in client Managed …

Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE

Dimensional Fund Advisors LP has reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 38.3%, selling 29,593 shares but retaining 47,697 shares valued at $2.4 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $111.69, while institutional investors collectively …

Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT

Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past …

Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Dimensional Fund Advisors LP reduced its stake in Rhythm Pharmaceuticals, Inc. by 40.2% in the first quarter, selling 12,867 shares and retaining 19,151 shares valued at approximately $1.67 million. Despite the sale, Rhythm Pharmaceuticals reported strong quarterly revenue growth of 46.9% year-over-year and beat …

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

Assenagon Asset Management S.A. Increases Stake in Fortrea Holdings Inc. $FTRE

Assenagon Asset Management S.A. significantly increased its stake in Fortrea Holdings Inc. by 90.7% in Q2 2026, now owning 173,129 shares valued at $3.0 million. This comes as Fortrea reported strong quarterly results, beating EPS and revenue estimates, while analysts maintain a "Hold" rating …

ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370

This article provides a detailed overview of ADMA Biologics Inc. (ADMA) stock, including its current price, market performance, key financial figures, and analyst ratings. It also offers technical analysis, company profile, ownership breakdown, and related instruments in the pharmaceutical sector.

Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System

Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX